Effects of intra-articular administration of sodium hyaluronate on plasminogen activator system in temporomandibular joints with osteoarthritis

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology

Volumn 109, Issue 4, 2010, Pages 541-547

  Tang, Ya ling ^a   Zhu, Gui quan ^a   Hu, Lei ^a   Zheng, Min ^a   Zhang, Jing yi ^a   Shi, Zong dao ^b   Liang, Xin hua ^a,b  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HYALURONIC ACID; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE; UROKINASE RECEPTOR; VISCOSUPPLEMENT;

ADULT; ARTICLE; CHEMISTRY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; INTRAARTICULAR DRUG ADMINISTRATION; MALE; MIDDLE AGED; OSTEOARTHRITIS; PAIN ASSESSMENT; POLYACRYLAMIDE GEL ELECTROPHORESIS; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SYNOVIAL FLUID; TEMPOROMANDIBULAR JOINT DISORDER;

ADULT; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; HUMANS; HYALURONIC ACID; INJECTIONS, INTRA-ARTICULAR; MALE; MIDDLE AGED; OSTEOARTHRITIS; PAIN MEASUREMENT; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATORS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; SINGLE-BLIND METHOD; SYNOVIAL FLUID; TEMPOROMANDIBULAR JOINT DISORDERS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; VISCOSUPPLEMENTS;

EID: 77949489939     PISSN: 10792104     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tripleo.2009.11.007     Document Type: Article

References (37)

1. Quinn J.H., and Bazan N.G. Identification of prostaglandin E2 and leukotriene B4 in the synovial fluid of painful, dysfunctional temporomandibular joints. J Oral Maxillofac Surg 48 (1990) 968-971
2. Song F., and Windsor L.J. Novel nonmatrix-metalloproteinase-mediated collagen degradation. Biochim Biophys Acta 1721 (2005) 65-72
3. Yeung R.W., Chow R.L., Samman N., and Chiu K. Short-term therapeutic outcome of intra-articular high molecular weight hyaluronic acid injection for nonreducing disc displacement of the temporomandibular joint. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102 (2006) 453-461
4. Goa K.L., and Benfield P. Hyaluronic acid. A review of its pharmacology and use as a surgical aid in ophthalmology, and its therapeutic potential in joint disease and wound healing. Drugs 47 (1994) 536-566
5. Marshall K.W. Intra-articular hyaluronan therapy. Curr Opin Rheumatol 12 (2000) 468-474
6. Knudson W., and Loeser R.F. CD44 and integrin matrix receptors participate in cartilage homeostasis. Cell Mol Life Sci 59 (2002) 36-44
7. Ohno S., Ohno-Nakahara M., Knudson C.B., and Knudson W. Induction of MMP-3 by hyaluronan oligosaccharides in temporomandibular joint chondrocytes. J Dent Res 84 (2005) 1005-1009
8. Takahashi T., Tominaga K., Takano H., Ariyoshi W., Habu M., and Fukuda J. A decrease in the molecular weight of hyaluronic acid in synovial fluid from patients with temporomandibular disorders. J Oral Pathol Med 33 (2004) 224-229
9. Bertolami C.N., Gay T., Clark G.T., Rendell J., Shetty V., Lin C., and Swann D.A. Use of hyaluronic acid in treating temporomandibular joint disorders: a randomized, double-blind, placebo-controlled clinical trial. J Oral Maxillofac Surg 5 (1993) 232-242
10. Bjornland T., Gjaerum A.A., and Moystad A. Osteoarthritis of the temporomandibular joint: an evaluation of the effects and complications of corticosteroid injection compared with injection with sodium hyaluronate. J Oral Rehabil 34 (2007) 583-589
11. Guarda-Nardini L., Stifano M., Brombin C., Salmaso L., and Manfredini D. A one-year case series of arthrocentesis with hyaluronic acid injections for temporomandibular joint osteoarthritis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 103 (2007) E14-E22
12. Guarda-Nardini L., Masiero S., and Marioni G. Conservative treatment of temporomandibular joint osteoarthrosis: intra-articular injection of sodium hyaluronate. J Oral Rehabil 32 (2005) 729-734
13. Irigoyen J.P., Munoz-Canoves P., Montero L., Koziczak M., and Nagamine Y. The plasminogen activator system: biology and regulation. Cell Mol Life Sci 56 (1999) 104-132
14. Rosso A.D., Cinelli M., Guiducc S., Pignone A., Fibbi G., Margheri F., et al. Deflazacort modulates the fibrinolytic pattern and reduces uPA-dependent chemioinvasion and proliferation in rheumatoid arthritis synoviocytes. Rheumatology 44 (2005) 1255-1262
15. Slot O., Brunner N., Locht H., Oxholm P., and Stephens R.W. Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis. Ann Rheum Dis 58 (1999) 488-492
16. Mondino A., and Blasi F. uPA and uPAR in fibrinolysis, immunity and pathology. Trends Immunol 25 (2004) 450-455
17. Busso N., Peclat V., So A., and Sappino A.P. Plasminogen activation in synovial tissues: differences between normal, osteoarthritis, and rheumatoid arthritis joints. Ann Rheum Dis 56 (1997) 550-557
18. Sakamaki H., Ogura N., Kujiraoka H., Akiba M., Abiko Y., and Nagura H. Activities of plasminogen activator, plasmin and kallikrein in synovial fluid from patients with temporomandibular joint disorders. Int J Oral Maxillofac Surg 30 (2001) 323-328
19. Zhu G., Tang Y., Liang X., Zheng M., Yang J., Zhou H., et al. Role of hypoxia-inducible factor-1 alpha in the regulation of plasminogen activator activity in rat knee joint chondrocytes. Osteoarthritis Cartilage 17 (2009) 1494-1502
20. Nonaka T., Kikuchi H., Ikeda T., Okamoto Y., Hamanishi C., and Tanaka S. Hyaluronic acid inhibits the expression of uPA, PAI-1, and uPAR in human synovial fibroblasts of osteoarthritis and rheumatoid arthritis. J Rheumatol 27 (2000) 997-1004
21. Dworkin S.F., and LeResche L. Research diagnostic criteria for temporomandibular disorders: review, criteria, examinations and specifications, critique. J Craniomand Disord 6 (1992) 301-355
22. Guarda-Nardini L., Tito R., Staffieri A., and Beltrame A. Treatment of patients with arthrosis of the temporomandibular joint by infiltration of sodium hyaluronate: a preliminary study. Eur Arch Otorhinolaryngol 259 (2002) 279-284
23. Altman R., and Moskowitz R. Intraarticular hyaluronic acid (Hyalgan) in the tretament of patients with osteoarthritis of the knee: a randomized clinical trial. J Rheumatol 25 (1998) 2203-2212
24. Kolarz G., Kotz R., and Hochmayer I. Long-term benefits and repeated tretament cycles of intraarticular hyaluronic acid (Hyalgan) in patients with osteoarthritis of the knee. Semin Arthritis Rheum 32 (2003) 310-319
25. Mensiteri M., Ambrosio L., Innace S., Perbellini A., and Nicolais L. Viscoelastic evaluation of different knee osteoarthritis therapies. J Mat Sci Mat Med 6 (1995) 130-137
26. Ghosh P., Read R., Armstrong S., Wilson D., Marshall R., and McNair P. The effects of intraarticular administration of hyaluronan in a model of early osteoarthritis in sheep. I. Gait analysis and radiological and morphological studies. Semin Arthritis Rheum 22 Suppl 1 (1993) 18-30
27. Heussen C., and Dowdle E.B. Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal Biochem 102 (1980) 196-202
28. Blasi F., and Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 3 (2002) 932-943
29. Schwab W., Gavlik J.M., Beichler T., Funk R.H., Albrecht S., Maqdolen V., Luther T., Kasper M., and Shakibaei M. Expression of the urokinase-type plasminogen activator receptor in human articular chondrocytes: association with caveolin and beta(1)-integrin. Histochem Cell Biol 115 (2001) 317-323
30. lida K., Kurita K., Tange K., and Yoshida K. Necrosis of the articular tubercle after repeated injections of sodium hyaluronate in temporomandibular joint. A case report. Int J Maxillofac Surg 27 (1998) 278-279
31. Laquerre T., Nouvellon M., Kraznowska K., Bruno M.C., Vittecoq O., et al. Septic arthritis due to Actinomyces naeslundii: report of a case. Joint Bone Spine 69 (2002) 499-501
32. Bernardeau C., Bucki B., and Liote F. Acute arthritis after intraarticular hyaluronate injection: onset of effusion without crystal. Ann Rheum Dis 60 (2001) 518-520
33. Chen A.L., Desai P., Adler E.M., and Di Cesare P.E. Granulomatous inflammation after Hylan G-F 20 viscosupplementation of the knee: a report of six cases. J Bone Joint Surg Am 84 (2002) 1142-1147
34. Hirota W. Intra-articular injection of hyaluronic acid reduces total amounts of leukotriene C-4, 6-keto-prostaglandin F-1 alpha, prostaglandin F-2 alpha and interleukin-1 beta in synovial fluid of patients with internal derangement in disorders of the temporomandibular joint. Br J Oral Maxillofac Surg 36 (1998) 35-38
35. Aihara S., Murakami N., Ishii R., et al. Effects of sodium hyaluronate on the nociceptive response of rats with experimentally induced arthritis. Folia Pharmacol Japon 100 (1992) 359-365
36. Gotoh S., Onaya J.-I., Abe M., et al. Effects of the molecular weight of hyaluronic acid and its action mechanisms on experimental joint pain in rats. Ann Rheum Dis 52 (1993) 817-822
37. Zhou J.L., Liu S.Q., Qiu B., Hu Q.J., Ming J.H., and Peng H. Effects of hyaluronan on vascular endothelial growth factor and receptor-2 expression in a rabbit osteoarthritis model. J Orthop Sci 14 (2009) 313-319